Malignant pleural mesothelioma · 8 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine monotherapy Variant #20 | — | R 14 213 | 56d | 3.4 mo | 7.5 mo | 2 | R 28 426 PFS proxy | 2 |
Gemcitabine and Vinorelbine Variant #01 | — | R 3 329 | 21d | — | ~6.7 mo | — | — | 2 |
Doxorubicin monotherapy Variant #10 | — | R 1 293 | 21d | ~6.0 mo | ~8.2 mo | ~9 | ~R 11 639 PFS proxy · indirect | 18 |
Vinorelbine monotherapy Variant #01 | — | R 583 | 21d | 3.4 mo | — | 5 | R 2 917 PFS proxy | 1 |
Pemetrexed monotherapy N/A - secondary systemic drug | — | R 69 | 21d | — | 9.7 mo | — | — | — |
Nivolumab monotherapy Variant #01 Partial | — | — | 14d | — | 10.2 mo | — | — | 1 |
Placebo Partial | — | — | — | — | 6.6 mo | — | — | 2 |
Best supportive care Partial | — | — | — | — | 7.3 mo | — | — | 1 |
8 of 8 regimens shown